CRISPR Therapeutics AG (CRSP)
| Market Cap | 4.03B |
| Revenue (ttm) | 202.83M |
| Net Income (ttm) | -239.59M |
| Shares Out | 85.35M |
| EPS (ttm) | -2.90 |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 1,943,413 |
| Open | 47.14 |
| Previous Close | 46.97 |
| Day's Range | 46.61 - 47.91 |
| 52-Week Range | 43.42 - 91.10 |
| Beta | 1.66 |
| Analysts | Buy |
| Price Target | 73.69 (+55.93%) |
| Earnings Date | Nov 5, 2024 |
About CRSP
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious human diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, immune-oncology and autoimmune, in vivo, and type 1 diabetes. The company’s lead product cand... [Read more]
Financial Performance
In 2023, CRISPR Therapeutics AG's revenue was $371.21 million, an increase of 30885.48% compared to the previous year's $1.20 million. Losses were -$153.61 million, -76.37% less than in 2022.
Financial StatementsAnalyst Forecast
According to 19 analysts, the average rating for CRSP stock is "Buy." The 12-month stock price forecast is $73.69, which is an increase of 55.93% from the latest price.
News
CRISPR Therapeutics AG (CRSP) Jefferies London Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies London Healthcare Conference November 20, 2024 11:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer and Chairman Conference Call ...
CRISPR Therapeutics AG (CRSP) Guggenheim Inaugural Healthcare Innovation Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) Guggenheim Inaugural Healthcare Innovation Conference November 12, 2024 2:00 PM ET Company Participants Samarth Kulkarni - CEO and Chairman Conference Call Partic...
CRISPR Therapeutics to Present at the Jefferies London Healthcare Conference
ZUG, Switzerland and BOSTON, Nov. 14, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious disea...
Crispr Therapeutics Q3 Earnings: No Casgevy Revenue, But Plenty Of Optimism
CRISPR Therapeutics' Casgevy, the first CRISPR/Cas9 gene editing therapy, shows promising results in treating Sickle Cell Disease and beta thalassemia but faces challenges in patient adoption and cost...
CRISPR Therapeutics Provides Business Update and Reports Third Quarter 2024 Financial Results
-CASGEVY™ approved for the treatment of patients 12 years of age and older with sickle cell disease (SCD) and transfusion-dependent beta thalassemia (TDT) in Switzerland and Canada-
Crispr Therapeutics: Poised For A Major Turnaround
Crispr Therapeutics, a leader in CRISPR/Cas9 biotechnology, recently received FDA and EMA approval for Casgevy, the first CRISPR/Cas9-based treatment for TDT and SCD. The partnership with Vertex Pharm...
Buying Opportunities In Biotech And Pharma With Bhavneesh Sharma
Kirk Spano and Bhavneesh Sharma talk biotech, pharma, and contrarian buying opportunities. AI is revolutionizing drug discovery by significantly speeding up the process and increasing the probability ...
Crispr Therapeutics: Prepare To Be Bored
CRISPR Therapeutics' stock may seem boring due to the slow FDA trial and rollout process, but it's a strong long-term investment. CASGEVY, their FDA-approved treatment for sickle cell disease and TDT,...
Crispr's Casgevy Launch: Promising Start, Uncertain Future
CRISPR Therapeutics' stock has been volatile, with cautious optimism following FDA approval for gene therapy targeting sickle cell disease. Q2 2024 earnings revealed slow commercialization of Casgevy,...
Crispr Therapeutics Q2 Earnings: Casgevy Updates Underline 'Blockbuster' Potential
Crispr Therapeutics AG reported no revenues from Casgevy in Q2 earnings, but noted positive progress with over 35 authorized treatment centers activated globally. Casgevy's complex treatment journey i...
CRISPR Therapeutics Provides Business Update and Reports Second Quarter 2024 Financial Results
-More than 35 authorized treatment centers (ATCs) activated globally for CASGEVY™ and approximately 20 patients have had cells collected across all regions as of mid-July-
Crispr Therapeutics: Beaten Down But Not Broken
CRISPR Therapeutics AG investors have endured a challenging bear market decline. CRSP's buying momentum has waned as it struggles to stay above the $50 support level. Crispr's pipeline is mainly in th...
CRISPR Therapeutics (CRSP) Presents at Goldman Sachs 45th Annual Global Healthcare Conference - Company Call Transcript
CRISPR Therapeutics AG (NASDAQ:CRSP) Company Conference Call June 11, 2024 9:20 AM ET Company Participants Sam Kulkarni - Chief Executive Officer Conference Call Participants Salveen Richter - Goldma...
Crispr Therapeutics, Futurism-Turning-Commercial, Defies 'Valuation' (Technical Analysis)
Crispr Therapeutics' new gene-editing protocol gives it a legitimate claim to be the future of medicine. That powered the stock back in 2020-21. But at some point, it'll take revenues and profits, not...
The 'Undercovered' Dozen From June 1-6
The "Undercovered" Dozen highlights twelve ideas from the previous month on stocks with limited coverage. Biotechs CRISPR Therapeutics, Voyager Therapeutics, and Alnylam Pharmaceuticals are covered al...
CRISPR Therapeutics AG (CRSP) Jefferies 2024 Global Healthcare Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) Jefferies 2024 Global Healthcare Conference June 5, 2024 10:00 AM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Participants ...
CRISPR Therapeutics to Participate in Upcoming Investor Conferences
ZUG, Switzerland and BOSTON, May 29, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas...
Final Trade: UAL, NKE, SLV & CRSP
The final trades of the day with CNBC's Melissa Lee and the Option Action traders.
CRISPR Therapeutics Strengthens Executive Leadership Team with Key Appointments
-Naimish Patel, M.D., appointed to Chief Medical Officer- -Julianne Bruno, M.B.A.
CRISPR Therapeutics AG (CRSP) BofA Securities 2024 Health Care Conference (Transcript)
CRISPR Therapeutics AG (NASDAQ:CRSP) BofA Securities 2024 Health Care Conference Call May 15, 2024 12:20 PM ET Company Participants Samarth Kulkarni - Chief Executive Officer Conference Call Particip...
CRISPR Therapeutics to Present at the Bank of America Securities Health Care Conference
ZUG, Switzerland and BOSTON, May 09, 2024 (GLOBE NEWSWIRE) -- CRISPR Therapeutics (Nasdaq: CRSP), a biopharmaceutical company focused on creating transformative gene-based medicines for serious diseas...
CRISPR Therapeutics Provides Business Update and Reports First Quarter 2024 Financial Results
-More than 25 authorized treatment centers (ATCs) activated globally for CASGEVY™ and multiple patients have already had cells collected-
CRISPR Therapeutics Highlights ASGCT Oral Presentation and Announces New Programs Utilizing In Vivo Gene Editing Approach
- ASGCT presentation demonstrates lipid nanoparticle (LNP) mediated delivery to the eye in the context of editing of the myocilin (MYOC) gene as a potential treatment for glaucoma -
Crispr Therapeutics: Market Misunderstanding Is Your Buying Opportunity (Upgrade)
Crispr Therapeutics AG stock has plunged deep into a bear market. The FOMO attributed to Crispr's Casgevy approvals is likely dissipated. Crispr has an expanding early-stage portfolio. Crispr is also ...
Invest In A Revolutionary Gene Therapy With CRISPR Therapeutics
CRISPR/Cas9 technology allows for precise editing of DNA, potentially treating human diseases by replacing entire genes. CRISPR Therapeutics has developed the first FDA-approved ex vivo CRISPR/Cas9 th...